KaydedilenlerDerginizi ekleyin

Dergiler / Gülhane Tıp Dergisi / 2018 / Cilt: 60 - Sayı: 4

Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers

İsmail ERTÜRK
Birol YILDIZ
NURİ KARADURMUŞ
BETÜL TOSUN
RAMAZAN ESEN
RAMAZAN ACAR
Murat URKAN
Gökhan ERDEM
Sayfa
145–150
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Additionally, GOP treatment was associated with cognitive side effects in patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age.
📊
Temel Bulgular & Veri:We aimed to demonstrate the real-life data of progressive testicular cancer patients who received GOP treatment.
💡
Sonuç & Katkı:Additionally, GOP treatment was associated with cognitive side effects in patients.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aims: Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age. Testicular cancer patients are treated with the combination of gemcitabine, oxaliplatin and paclitaxel (GOP) in relapsed and refractory disease, but the literature about the GOP treatment is limited. We aimed to demonstrate the real-life data of progressive testicular cancer patients who received GOP treatment. Methods: Medical records of 17 patients who received GOP treatment at the Gulhane Training and Research Hospital were reviewed retrospectively. Overall response rate (ORR), overall survival (OS) rate and progression-free survival (PFS) of the patients were evaluated. Results: Overall response was obtained in 58.8% (n=10), and a complete response was achieved in 11.2% (n=2) of the cases. OS time was 14.2 months and the OS rate in the first year was 73.1%. The PFS time was 7.6 months. In most of the patients, thrombocytopenia, anemia and leukopenia were observed during GOP treatment. Conclusions: GOP is a safe and effective treatment option for relapsed refractory testicular cancer patients with an acceptable ORR, OS and PFS time. Additionally, GOP treatment was associated with cognitive side effects in patients.

🔖

Bu Makaleye Atıf Yap

ERTÜRK, İ., YILDIZ, B., KARADURMUŞ, N., TOSUN, B., ESEN, R., ACAR, R., URKAN, M., ERDEM, G. (2018). Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers. Gülhane Tıp Dergisi, Cilt: 60 - Sayı: 4, 145–150. https://ajindex.com/articles/166086

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Bosl GJ, Motzer RJ. Medical progress: testicular germcell cancer. N Engl J Med. 1997;337(4):242–253. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 2002;99(7):4592-4595.
  2. Hanna NH, Einhorn LH. Testicular cancer discoveries and updates. N Engl J Med. 2014;371(21):2005-2016.
  3. Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol. 2000;18(6):1181-1186.
  4. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refrac tory testicular cancer. Ann Oncol. 1996;7(1):31–34.
  5. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 1999;17(2):509–511.
  6. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002; 20(8):2031–2037.
  7. Motzer RJ, Bajorin D, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol. 1994;12(11):2277–2283.
  8. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22(1):108–114.
  9. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19(3):448- 453. Oechsle K, Kollmannsberger C, Honecker F, et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. European Urology 2011;60(4):850-855.
  10. Hinton S, Catalano P, Einhorn LH, et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol. 2001;20(7):1859–1863.
  11. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15(3):493–497.
  12. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-ref